Crestline Management, LP Gilead Sciences, Inc. Transaction History
Crestline Management, LP
- $2.93 Billion
- Q4 2024
A detailed history of Crestline Management, LP transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Crestline Management, LP holds 46,779 shares of GILD stock, worth $4.87 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
46,779
Previous 40,904
14.36%
Holding current value
$4.87 Million
Previous $3.43 Million
26.02%
% of portfolio
0.15%
Previous 0.18%
Shares
9 transactions
Others Institutions Holding GILD
# of Institutions
2,082Shares Held
1.02BCall Options Held
8.81MPut Options Held
9.7M-
Black Rock Inc. New York, NY121MShares$12.6 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA116MShares$12 Billion0.19% of portfolio
-
Capital World Investors Los Angeles, CA71.7MShares$7.46 Billion1.05% of portfolio
-
State Street Corp Boston, MA60.4MShares$6.28 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA57.9MShares$6.03 Billion1.15% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $130B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...